三星医疗公告，下属全资子公司巴西南森签订巴西CPFL智能电表项目合同，合同金额总计1.06亿雷亚 尔，约合1.35亿人民币，占公司2024年度经审计营业收入的0.92%。公司将提供单相和三相智能电表等 产品。该合同的签订是公司积极拓展海外市场、深化本地化布局的重要成果，有助于提升公司的海外市 场竞争力。合同的履行将对公司经营业绩产生积极影响。 ...

人民财讯12月24日电，三星医疗（601567）12月24日公告，下属全资子公司巴西南森签订巴西CPFL智 能电表项目合同，合同金额总计1.06亿雷亚尔，约合1.35亿元人民币，占公司2024年度营业收入的 0.92%。 ...

Group 1 - The core point of the article is that Samsung Medical (601567.SH) has signed a contract for a smart meter project in Brazil with CPFL, amounting to 105.9099 million Brazilian Reais, which is approximately 135 million Chinese Yuan [1] Group 2 - The contract is executed through Nansen Instrumentos de Precisão Ltda, a wholly-owned subsidiary of Samsung Medical [1] - The project signifies Samsung Medical's expansion into the Brazilian market, particularly in the smart meter sector [1] - The financial implications of the contract could enhance the company's revenue and market presence in Latin America [1]

证券日报网讯12月23日，三星医疗（601567）在互动平台回答投资者提问时表示，公司主营业务为智能 配用电及医疗服务两大板块，未涉及可控核聚变领域。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司是否涉及可控核聚变领域？ 三星医疗（601567.SH）12月23日在投资者互动平台表示，公司主营业务为智能配用电及医疗服务两大 板块，未涉及可控核聚变领域。 ...

针对上述提问，三星医疗回应称："尊敬的投资者，您好！公司主营业务为智能配用电及医疗服务两大 板块，未涉及可控核聚变领域。感谢您的关注！" 有投资者在互动平台向三星医疗提问："贵司是否涉及可控核聚变领域？" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

格隆汇12月23日丨三星医疗(601567.SH)在投资者互动平台表示，公司主营业务为智能配用电及医疗服 务两大板块，未涉及可控核聚变领域。 ...

Overview of Guarantees - The company has signed a guarantee contract with Bank of Communications for a maximum principal amount of RMB 440 million, effective from December 1, 2025, to December 1, 2030 [1] - The company has also signed a maximum guarantee contract with Agricultural Bank of China for a maximum principal amount of RMB 675 million, effective from December 10, 2025, to December 9, 2028 [1] - The company applied for a letter of guarantee from Standard Chartered Bank for USD 100,000 (approximately RMB 716,200), with an initial validity until April 10, 2026, which has been extended to May 15, 2026 [2] Internal Decision-Making Process - The company’s board of directors approved the guarantee proposals on April 24, 2025, and the annual shareholders' meeting on May 16, 2025, allowing for a total guarantee amount of up to RMB 974.85 million, with RMB 450 million specifically for the subsidiary [2] Financial Health of the Guaranteed Entity - The subsidiary, Aux Smart Technology, has a debt-to-asset ratio of 68.93% as of the end of 2024, indicating a significant level of leverage [2] Details of Guarantee Agreements - The guarantee to Bank of Communications covers all principal debts and associated costs, with a maximum guarantee amount of RMB 440 million [4][5] - The guarantee to Agricultural Bank of China also includes all principal debts and associated costs, with a maximum guarantee amount of RMB 675 million [7][8] Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to meet the funding needs of the subsidiary and ensure its stable operations, with the company maintaining control over the subsidiary's financial health [9] Board of Directors' Opinion - The board believes that providing guarantees to the subsidiary is based on actual operational needs and that the associated risks are manageable [10] Cumulative Guarantee Amounts - As of the announcement date, the total amount of guarantees provided by the company to its subsidiaries is RMB 975.35 million, which represents 80.73% of the company's net assets attributable to shareholders for the year 2024 [10]

证券代码：601567 证券简称：三星医疗 公告编号：临2025-095 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 担保对象 被担保人名称 宁波奥克斯智能科技股份有限公司（以 下简称"奥克斯智能科技"） 本次担保金额 111,571.62 万人民币 实际为其提供的担保余额 446,331.62 万元（含本次担保） 是否在前期预计额度内 是 □否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 担保金额超过上市公司最近一期经审计净 | ...

Core Viewpoint - Samsung Medical is committed to advancing its digital transformation strategy to enhance patient experience and medical quality amid the aging population in China [1] Group 1: Financial Performance - For the period from January to September, Samsung Medical achieved a revenue of 11.08 billion yuan, representing a year-on-year growth of 6.19% [1] - The company reported a net profit attributable to shareholders of 1.528 billion yuan, which reflects a year-on-year decline of 15.85% [1] Group 2: Strategic Focus - The company is focusing on chain operations, discipline construction, and medical quality to deepen its engagement in the rehabilitation sector [1] - Continuous improvement in management and operational levels is a priority for the company [1]